Wednesday, February 05, 2025 10:00:06 AM
There was coverage of Elon Musk and they made fun of him chewing tobacco or dipping snuff. Other honchos do it to...Bill Gates and more. But the article did not say why other than hinting a bad habit because he is with the new President.
Anyone want to know the real reason why he partakes in such a "nasty" habit???? Of course the MSM did not tell us why!!
Anyone want to know the real reason why he partakes in such a "nasty" habit???? Of course the MSM did not tell us why!!
Recent TELO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 07:09:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:15:41 PM
- Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer • ACCESS Newswire • 04/30/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 01:00:13 PM
- Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) • ACCESS Newswire • 04/24/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 01:15:16 PM
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer • ACCESS Newswire • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:00:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/17/2026 09:28:20 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 02/19/2026 10:16:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/19/2026 10:12:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:00:48 PM
- Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models • ACCESS Newswire • 02/17/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging • ACCESS Newswire • 02/05/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 12:30:43 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 01/23/2026 10:04:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 01:00:54 PM
- Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models • ACCESS Newswire • 01/05/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development • ACCESS Newswire • 12/18/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2025 09:01:45 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 11/28/2025 09:59:00 PM
- Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells • ACCESS Newswire • 11/25/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2025 09:01:40 PM
